Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
Patients with suspected lung cancer will be able to access specialist diagnostic testing faster and closer to home following the launch of a new robotic bronchoscopy service at St Mary's Hospital, the first in north west London.
Imperial College Healthcare…
Attendees
Sponsors and Exhibitors
Contact us